Incretin Effect in People With Impaired Fasting Glucose
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
Regulation of endogenous glucose production (EGP) and insulin secretion are major actions of
glucagon-like peptide-1 (GLP-1). Determining whether alterations in GLP-1 may contribute to
abnormal EGP and insulin secretion in people with impaired fasting glucose (IFG) was the
objective of the current study. The investigators hypothesized that defects in GLP-1 may
explain the inappropriate basal EGP and diminished insulin secretion in IFG, and,
furthermore, that by increasing circulating GLP-1 levels (using a new medicine called
"sitagliptin") the investigators could reverse these defects.